Why Is TARSUS PHARMACEUTICA (TARS) Stock Up Today?

TARS stock rose 11.74% to $82.75 on September 2, 2026 driven by a combination of recent corporate developments and investor interest. The stock opened at a 2.8% discount to the prior close but quickly reversed course, reaching a session high of $82.75. The move followed the company's announcement of its participation in upcoming investor conferences and news of a potential acquisition of Alkeus Pharmaceuticals.

What Happened

Tarsus Pharmaceuticals announced that its management will attend the Wells Fargo investor conference, signaling a focus on engaging with the investment community. This news came alongside a previously undisclosed agreement to acquire Alkeus Pharmaceuticals, a biotech firm developing an investigational therapy for Stargardt disease. The acquisition terms include $450 million upfront in cash and stock, with up to $350 million in additional milestones. Alkeus's gildeuretinol is in Phase 3 trials, adding potential value to Tarsus’s pipeline. Additionally, Oppenheimer recently raised its price target for Tarsus to $100, maintaining an Outperform rating, which may have further fueled investor optimism.

What The Data Shows

The stock opened at $72.00, but surged throughout the session to reach $82.75, with volume of 0.6 million shares, representing 70% of the 3-month average. Over the past eight trading sessions, the stock has risen 8.5%, from $72.81 to $79.02. Tarsus has also printed 57 fresh 52-week highs on September 2, 2026. On the fundamentals, the company has a market cap of $3.3 billion and reported revenue growth of 105.2% in the trailing twelve months, despite an unprofitable EPS of -1.08. Notably, insiders have sold a total of $2.5 million in shares over the past 90 days, with the most recent filing on June 22.

What To Watch

Tarsus Pharmaceuticals is scheduled to report earnings on August 30, 2026, but no further corporate actions are currently scheduled. Investors will likely monitor the stock's reaction to the acquisition of Alkeus and the progress of the Stargardt disease therapy.